
Omeros Corporation OMER
$ 20.08
0.22%
Omeros Corporation Gross Profit | OMER
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Omeros Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 111 M | 29.4 M | 63.7 M | 40.2 M | 12.5 M | - | - | - | 4.52 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 111 M | 4.52 M | 43.5 M |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Clovis Oncology
CLVS
|
123 M | - | -7.23 % | $ 13 M | ||
|
Concert Pharmaceuticals
CNCE
|
7.9 K | - | - | $ 401 M | ||
|
BioMarin Pharmaceutical
BMRN
|
1.34 B | $ 60.26 | 0.06 % | $ 11.6 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
2.03 M | $ 2.17 | 0.46 % | $ 3.57 M | ||
|
Genocea Biosciences
GNCA
|
1.36 K | - | -15.0 % | $ 3.04 M | ||
|
Catalyst Biosciences
CBIO
|
102 M | $ 13.99 | 0.84 % | $ 1.25 B | ||
|
C4 Therapeutics
CCCC
|
33.2 M | $ 2.98 | 0.3 % | $ 247 M | ||
|
Codexis
CDXS
|
52.8 M | $ 1.32 | 1.09 % | $ 115 M | ||
|
Amryt Pharma plc
AMYT
|
116 M | - | - | $ 621 M | ||
|
Cerus Corporation
CERS
|
60.4 M | $ 2.62 | 0.38 % | $ 499 M | ||
|
Coherus BioSciences
CHRS
|
339 M | $ 1.13 | 0.43 % | $ 132 M | ||
|
Celldex Therapeutics
CLDX
|
5.48 M | $ 31.1 | 1.16 % | $ 2.07 B | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
1.54 M | $ 4.25 | 3.16 % | $ 51.9 M | ||
|
AbbVie
ABBV
|
12.1 B | $ 264.34 | 0.09 % | $ 468 B | ||
|
Cocrystal Pharma
COCP
|
7.22 M | $ 1.17 | 1.74 % | $ 13.2 M | ||
|
Abeona Therapeutics
ABEO
|
925 K | $ 5.4 | 2.65 % | $ 286 M | ||
|
Collegium Pharmaceutical
COLL
|
128 M | $ 22.53 | 0.2 % | $ 713 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
301 M | $ 116.1 | 4.93 % | $ 12.1 B | ||
|
Фармсинтез
LIFE
|
160 M | - | - | - | ||
|
Cardiff Oncology
CRDF
|
245 K | $ 1.24 | 0.74 % | $ 82.9 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
3.94 M | $ 7.14 | 0.19 % | $ 95.1 M | ||
|
Curis
CRIS
|
9.5 M | $ 0.83 | 1.1 % | $ 10.9 M | ||
|
CorMedix
CRMD
|
276 M | $ 7.85 | 1.03 % | $ 565 K | ||
|
Champions Oncology
CSBR
|
12.8 M | $ 4.9 | 0.1 % | $ 67.8 M | ||
|
Chimerix
CMRX
|
212 K | - | - | $ 756 M | ||
|
Cue Biopharma
CUE
|
3.15 M | $ 31.41 | 1.45 % | $ 2.98 B | ||
|
CEL-SCI Corporation
CVM
|
255 K | $ 1.67 | 2.38 % | $ 13.4 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
-40.6 M | $ 4.85 | 0.2 % | $ 929 M | ||
|
Cytokinetics, Incorporated
CYTK
|
-57.6 M | $ 64.66 | 0.17 % | $ 7.77 M | ||
|
Daré Bioscience
DARE
|
80 K | $ 0.78 | 4.73 % | $ 8.72 M |